Ramona Dadu, M.D.

Peer-Reviewed Articles

1. Maniakas A, Wilde DC, Fournier I, Hyde EK, Xu L, Wang JR, Gross ND, Sturgis EM, Banuchi V, Busaidy NL, Cabanillas ME, Iyer P, Dadu R, Waguespack SG, Hu MI, Gunn GB, Kwon M, Ahmed S, Williams MD, Zafereo ME. Segmental Tracheal Resection for Thyroid Cancer: Perioperative Morbidity, Locoregional Control, and Survival. Head Neck, 2025. e-Pub 2025. PMID: 41059669.
2. Fournier I, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head Neck, 2025. e-Pub 2025. PMID: 40891104.
3. Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques. Head Neck, 2025. e-Pub 2025. PMID: 40747656.
4. Cabanillas, ME, Busaidy, NL, Gunn, GB, Iyer, PC, Ferrarotto, R, Gule-Monroe, MK, Maniakas, A, Williams, MD, Liu, S, Fellman, B, Spiotto, MT, Hamidi, S, Akhave, NS, Lee, A, Wang, RJ, De Sousa, LG, Marczyk, VR, Zafereo, M, Dadu, R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
5. Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann MC, Hosseini SM, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. J Clin Endocrinol Metab, 2025. e-Pub 2025. PMID: 40568752.
6. Hamidi, S, Dadu, R, Iyer, PC, Busaidy, NL, Maniakas, A, Wang, RJ, Banuchi, VE, Hosseini, SM, Williams, MD, Zafereo, M, Cabanillas, ME. Circulating Tumor DNA as a Biomarker for Disease Surveillance in Anaplastic Thyroid Cancer. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40570261.
7. Cabanillas, ME, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Gunn, GB, Hamidi, S, Hofmann, M, Hosseini, SM, Iyer, PC, Lai, SY, Lee, A, Maniakas, A, Ning, M, Spiotto, MT, Wang, RJ, Williams, MD, Zafereo, M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
8. Houl JH, Bagheri-Yarmand R, Kunnimalaiyaan M, Miranda Mendez P, Kidd JL, Dadbin A, Jurado Ruiz A, Parekh PA, Henderson YC, Chari NS, Thennavan AT, Powell RT, Stephan CC, Zhao X, Maniakas A, Nurieva R, Busaidy NL, Cabanillas ME, Dadu R, Zafereo M, Wang JR, Lai SY, Hofmann MC. Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells. bioRxiv, 2025. e-Pub 2025. PMID: 40027641.
9. Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
10. Hamidi S, Ning MS, Phan J, Zafereo ME, Gule-Monroe MK, Dadu R. Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy. JCEM Case Rep 3(2):luaf015, 2025. e-Pub 2025. PMID: 39866918.
11. Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39662038.
12. Dagher SA, Learned KO, Dagher R, Wang JR, Zhao X, Hosseini SM, Maniakas A, Cabanillas ME, Busaidy NL, Dadu R, Iyer P, Zafereo ME, Khalaf AM. [18F]-Fluorodeoxyglucose Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma Following BRAF-Targeted Therapy. AJNR Am J Neuroradiol 46(6):1260-1267, 2024. e-Pub 2024. PMID: 39572200.
13. Bronk JK, Augustyn A, Mohamed ASR, David Fuller C, Garden AS, Moreno AC, Lee A, Morrison WH, Phan J, Reddy JP, Rosenthal DI, Spiotto MT, Frank SJ, Dadu R, Busaidy N, Zafereo M, Wang JR, Maniakas A, Ferrarotto R, Iyer PC, Cabanillas ME, Gunn GB. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiother Oncol 202:110602, 2024. e-Pub 2024. PMID: 39489425.
14. Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol 10(12):1672-1680, 2024. e-Pub 2024. PMID: 39446377.
15. Iyer PC, Dadu R, Barque A, Zanelli C, Zheng X, Jiang H, Walsh PS, Hao Y, Huang J, Klopper J, Kloos RT, Cabanillas M. Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay. J Clin Endocrinol Metab 109(9):2269-2273, 2024. e-Pub 2024. PMID: 38441247.
16. Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol 10(9):1264-1271, 2024. e-Pub 2024. PMID: 38990526.
17. French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res 30(17):3757-3767, 2024. e-Pub 2024. PMID: 38922338.
18. Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier N, Brown S, Holla VR, Dadu R, Busaidy N, Sherman SI, Cabanillas M, Waguespack SG, Zafereo ME, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. J Endocr Soc 8(6):bvae048, 2024. e-Pub 2024. PMID: 38660141.
19. Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol 8(1):62, 2024. e-Pub 2024. PMID: 38438731.
20. Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 34(3):336-346, 2024. e-Pub 2024. PMID: 38226606.
21. Maniakas A, Sullivan A, Hu MI, Busaidy NL, Cabanillas ME, Dadu R, Waguespack SG, Fisher SB, Graham PH, Gross ND, Grubbs EG, Perrier ND, Wang JR, Gunn B, Garden AS, Megahed R, Navuluri S, Li X, Williams MD, Zafereo M. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck 46(2):328-335, 2024. e-Pub 2024. PMID: 38009416.
22. Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, Shiau CK, Pan T, Yan Y, Tran TM, Li J, Kieser R, Zhao X, Wang J, Nurieva R, Williams MD, Cabanillas ME, Dadu R, Busaidy NL, Zafereo M, Navin N, Lai SY, Gao R. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J Clin Invest 133(11), 2023. e-Pub 2023. PMID: 37053016.
23. Jeun R, Iyer PC, Best C, Lavis V, Varghese JM, Yedururi S, Brady V, Glitza Oliva IC, Dadu R, Milton DR, Brock K, Thosani S. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy 15(6):417-428, 2023. e-Pub 2023. PMID: 37013834.
24. Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid 33(4):484-491, 2023. e-Pub 2023. PMID: 36762947.
25. Shenson JA, Zafereo ME, Lee M, Contrera KJ, Feng L, Boonsripitayanon M, Gross N, Goepfert R, Maniakas A, Wang JR, Grubbs L, Vaporciyan A, Hofstetter W, Swisher S, Mehran R, Rice D, Sepesi B, Antonoff M, Cabanillas M, Busaidy N, Dadu R, Silver NL. Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer. Head Neck 45(3):547-554, 2023. e-Pub 2023. PMID: 36524701.
26. Chen YH, Cabanillas M, Sperling J, Xu L, Goswami M, Maniakas A, Williams MD, Lai SY, Busaidy N, Dadu R, Zafereo ME, Wang JR. Prior Thyroid and Nonthyroid Cancer History Do Not Significantly Alter Overall Survival in Patients Diagnosed with Anaplastic Thyroid Cancer. Thyroid 33(3):321-329, 2023. e-Pub 2023. PMID: 36511380.
27. Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid 33(1):129-132, 2023. e-Pub 2023. PMID: 36503246.
28. Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol 6:e2100504, 2022. e-Pub 2022. PMID: 35977347.
29. Maniakas A, Henderson YC, Hei H, Peng S, Chen Y, Jiang Y, Ji S, Cardenas M, Chiu Y, Bell D, Williams MD, Hofmann MC, Scherer SE, Wheeler DA, Busaidy NL, Dadu R, Wang JR, Cabanillas ME, Zafereo M, Johnson FM, Lai SY. Novel anaplastic thyroid cancer PDXs and cell lines: Expanding preclinical models of genetic diversity. J Clin Endocrinol Metab 106(11):e4652-e4665, 2021. e-Pub 2021. PMID: 34147031.
30. Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid 31(8):1235-1243, 2021. e-Pub 2021. PMID: 33599171.
31. Abdel-Wahab N, Diab A, Yu RK, Futreal A, Criswell LA, Tayar JH, Dadu R, Shannon V, Shete SS, Suarez-Almazor ME. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunol Immunother 70(7):1939-1949, 2021. e-Pub 2021. PMID: 33409738.
32. Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer 28(7):419-431, 2021. e-Pub 2021. PMID: 33890870.
33. Bagheri-Yarmand R, Dadu R, Ye L, Shiny Jebaraj Y, Martinez JA, Ma J, Tarapore RS, Allen JE, Sherman SI, Williams MD, Gagel RF. ONC201 shows anti-cancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther 20(4):665-675, 2021. e-Pub 2021. PMID: 33536187.
34. Kim ST, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor ME. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 13(6):465-475, 2021. e-Pub 2021. PMID: 33641345.
35. Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1):1877415, 2021. e-Pub 2021. PMID: 33643693.
36. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck 43(1):E7-E12, 2021. e-Pub 2021. PMID: 33169506.
37. Datar S, Cabanillas M, Dadu R, Ost D, Grosu HB. Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents. BMC Cancer 20(1):1181, 2020. e-Pub 2020. PMID: 33267782.
38. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. e-Pub 2020. PMID: 33097651.
39. Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired secondary RAS mutation in BRAFV600E mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 30(9):1288-1296, 2020. e-Pub 2020. PMID: 32216548.
40. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol 6(9):1397-1404, 2020. e-Pub 2020. PMID: 32761153.
41. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
42. Dadu R, Rodgers TE, Trinh VA, Kemp EH, Cubb TD, Patel S, Simon JM, Burton EM, Tawbi H. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32581059.
43. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
44. Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036-1043, 2019. e-Pub 2019. PMID: 31319771.
45. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
46. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7(1):93, 2019. e-Pub 2019. PMID: 30940209.
47. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7(1):31, 2019. e-Pub 2019. PMID: 30728076.
48. Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 35135166.
49. Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Ann Surg Oncol 25(11):3380-3388, 2018. e-Pub 2018. PMID: 30022274.
50. Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with immune Checkpoint Inhibitors. Thyroid 28(10):1243-1251, 2018. e-Pub 2018. PMID: 30132401.
51. Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab 103(10):3698-3705, 2018. e-Pub 2018. PMID: 30032208.
52. Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy N, Cabanillas M, Dadu R, Sherman SI, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier N, Sturgis E, Zafereo M. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging 7th and 8th editions. Thyroid. e-Pub 2018. PMID: 30141373.
53. Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):68, 2018. e-Pub 2018. PMID: 29996921.
54. Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid 28(7):945-951, 2018. e-Pub 2018. PMID: 29742974.
55. Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plast Reconstr Surg. e-Pub 2018. PMID: 29927883.
56. Jaber T, Hyde SM, Cote GJ, Grubbs EG, Giles WH, Stevens CA, Dadu R. A homozygous RET K666N genotype with an MEN2A phenotype. J Clin Endocrinol Metab 103(4):1269-1272, 2018. e-Pub 2018. PMID: 29408964.
57. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid 28(1):79-87, 2018. e-Pub 2018. PMID: 29161986.
58. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS, Working Group SFIOCTM. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95, 2017. e-Pub 2017. PMID: 29162153.
59. Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. e-Pub 2017. PMID: 29044788.
60. Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid 27(5):672-681, 2017. e-Pub 2017. PMID: 28068873.
61. Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):jc20162815, 2016. e-Pub 2016. PMID: 27662441.
62. Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RET K666N Mutation. Thyroid 26(12):1744-1751, 2016. e-Pub 2016. PMID: 27673361.
63. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 51(2):351-9, 2016. e-Pub 2016. PMID: 26206754.
64. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
65. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. J Clin Endocrinol Metab 100(1):jc20142246, 2015. e-Pub 2015. PMID: 25353071.
66. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
67. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24(5):918-22, 2014. e-Pub 2014. PMID: 24635127.
68. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
69. Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 19(3):251-8, 2014. e-Pub 2014. PMID: 24563075.
70. Dumitrascu DL, Nedelcu L, Pop S, Blaga-Surdea T, Dadu RT, Costin S, Popescu M, Picos A, David L. The use of complementary and alternative therapies and of psychotherapy by Romanian patients with irritable bowel syndrome. Rom J Intern Med 51(3-4):148-51, 2013. e-Pub 2013. PMID: 24620627.
71. Dadu RT, Dadu R, Saul Z. An unusual presentation of endocarditis with nutritional variant streptococci. Clujul Medical 86(2):153-1155, 2013. e-Pub 2013.
72. Dadu RT, Dadu R, Zane S. Unusual presentation of endocarditis with nutritional variant Streptococci. Clujul Med 86(2):153-5, 2013. e-Pub 2013. PMID: 26527938.
73. Kaufman DA, Ravi S, Dadu R, Horowitz D, Logue MA. Severe hypoxemia and orthodeoxia following right pneumonectomy. Am J Respir Crit Care Med 184(11):e1-2, 2011. e-Pub 2011. PMID: 22162892.
74. Casanegra AI, Brannan S, Dadu R, Ong P, Berner M, Spinning K, Hughes T, Marrinan G, Zinn K, Manthous C. Short-term femoral vein catheterization rarely causes thrombosis or bacteremia. J Hosp Med 6(1):33-6, 2011. e-Pub 2011. PMID: 20578050.
75. Gheorghe C, Vazquez R, Casanegra AI, Argento V, Dadu R, Feng Y, Amoateng-Adjepong Y, Manthous CA. Elders' environs and their end-of-life preferences. J Am Med Dir Assoc 12(1):22-8, 2011. e-Pub 2011. PMID: 21194655.
76. Parperis K, Dadu R, Hoq S, Argento V. Thyrotoxic Dysphagia in an 82-year-old male. Case Rep Med 2011:929523, 2011. e-Pub 2011. PMID: 21317989.
77. Gheorghe C, Dadu R, Blot C, Barrantes F, Vazquez R, Berianu F, Feng Y, Feintzig I, Amoateng-Adjepong Y, Manthous CA. Hyperchloremic metabolic acidosis following resuscitation of shock. Chest 138(6):1521-2, 2010. e-Pub 2010. PMID: 21138891.
78. Odigie-Okon E, Jordan B, Dijeh S, Wolff A, Dadu R, Lall P, Zarich S, Amoateng-Adjepong Y, Manthous CA. Cardiac injury in patients with COPD presenting with dyspnea: a pilot study. Int J Chron Obstruct Pulmon Dis 5:395-9, 2010. e-Pub 2010. PMID: 21103406.
79. Vazquez R, Gheorghe C, Ramos F, Dadu R, Amoateng-Adjepong Y, Manthous CA. Gurgling breath sounds may predict hospital-acquired pneumonia. Chest 138(2):284-8, 2010. e-Pub 2010. PMID: 20348197.
80. Pop M, Ghigolea I, Muresan A, Râjnoveanu R, Dadu R, Pui A. [Tuberculosis or sarcoidosis]. Rev Med Chir Soc Med Nat Iasi 112(4):959-64, 2008. e-Pub 2008. PMID: 20209770.
81. Muresan C, Jude R, Neag M, Sandor V. Pain Tolerance and Behavioral Changes after Ovariectomy In Rats. Algezie si Analgezie 1:132-138, 2005. e-Pub 2005.
82. Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, Yan Y, Tran T, Li J, Shiau CK, Kieser R, Zhao X, Wang J, Nurieva R, Williams M, Zafereo M, Cabanillas ME, Dadu R, Busaidy NL, Navin N, Lai SY, Gao R. Anaplastic Transformation Continuum of Thyroid Cancer. Nature Medicine.

Invited Articles

1. Jaber T, Dadu R, Hu MI. Medullary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes 28(5):540-546, 2021. e-Pub 2021. PMID: 34292174.
2. Dadu R, Bagheri-Yarmand R, Ringel MD, Grubbs EG, Zafereo M, Cote G, Gagel RF, Robinson BG, Shaw KR, Hu MI. The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocr Relat Cancer 27(8):T27-T39, 2020. e-Pub 2020. PMID: 32580150.
3. Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000 Faculty Reviews 7(87), 2018. e-Pub 2018.
4. Cabanillas ME, Busaidy NL, Khan SA, Brandon Gunn G, Dadu R, Rao SN, Waguespack SG. Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. International Journal of Endocrine Oncology, 2017. e-Pub 2017.
5. Dadu R, Zobniw C, Diab A. Managing Adverse Events with Immune Checkpoint Agents. Cancer J 22(2):121-9, 2016. e-Pub 2016. PMID: 27111908.
6. Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am 29(6):1123-43, 2015. e-Pub 2015. PMID: 26568552.
7. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Horm Cancer 6(1):21-36, 2015. e-Pub 2015. PMID: 25467940.
8. Dadu R, Hu MN, Grubbs EG, Gagel RF. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Recent Results Cancer Res 204:227-49, 2015. e-Pub 2015. PMID: 26494392.
9. Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol 37(4):335-56, 2012. e-Pub 2012. PMID: 23235190.
10. Dadu R, Feng Y, Shimshi M. Severe hypertriglyceridemia-a case report and topic review. Lipin Spin 8(1):3-7, 2010. e-Pub 2010.

Review Articles

1. Iyer PC, Kikani N, Khan S, Chaudhari A, Pagnotti G, Best C, Weitzman S, Mehta P, Lavis V, Thosani S, Gandhi A, Aguirre RS, Varghese J, Guise T, Dadu R. The evolving management of endocrine disorders induced by checkpoint inhibitors: insights from the CIITED group. Expert Rev Endocrinol Metab:1-13, 2025. e-Pub 2025. PMID: 41307239.
2. Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne) 14:1176731, 2023. e-Pub 2023. PMID: 37435488.
3. Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Res 7, 2018. e-Pub 2018. PMID: 31583077.

Professional Educational Materials

1. Dadu R. Multiple Endocrine Neoplasia Type 1. Cancer.net, 2019.
2. Dadu R. Multiple Endocrine Neoplasia Type 2. Cancer.net, 2019.
3. Dadu R. Co-managing Thyroid Cancer in the Era of Personalized Medicine. Medscape Oncology Education, 2014.
4. Dadu R. Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients with Differentiated Thyroid Cancer. The Oncologist, 2014.
5. Dadu R. Sorafenib in Metastatic Thyroid Cancer-A Systematic Review. The Oncologist, 2014.

Other Articles

1. Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME Erratum. JCO Precision Oncology 9, 2025. PMID: 40632979.
2. Dadu R BRAF-Inhibitor Vemurafenib Show Promise in Metastatic Papillary Thyroid Cancer. Oncology Times 2(1):5, 2014.

Abstracts

1. Cabanillas ME, Busaidy NL, Iyer PC, Wang JR, Hu MI, Zafereo ME, Ferrarotto R, Lee A, Liu S, Gunn GB, Spiotto M, Hamidi S, Akhave N, de Sousa L, Maniakas A, Williams MD, Banuchi VE, Hosseini SM, Dadu R. Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in Anaplastic Thyroid Cancer (ATC): A Phase 2, Single Center Trial. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
2. Ahmad Abubaker MD, Isabelle Fournier MD, Mark Zafereo MD, Jennifer R Wang MD, Victoria Banuchi MD, Elizabeth G Grubbs MD, Paul H Graham MD, Naifa L Busaidy MD, Maria E Cabanillas MD, Ramona Dadu MD, Sarah Hamidi MD, Mimi I Hu MD, Priyanka Iyer MD, Steven I Sherman MD, Steven G Waguespack MD, Sachin Kumar Gupta MS, Salmaan Ahmed MD, Michael Kwon MD, Michelle D Williams MD, S Mohsen Hosseini MD, Anastasios Maniakas MD. Surgical Management of Isthmus-confined Papillary Thyroid Carcinoma: A single Institution Retrospective Cohort Study. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
3. Arpi Palacios JE, Fournier I, Maniakas A, Wang JR, Banuchi VE, Lango MN, Gule-Monroe MC, Williams MD, Mena M, Grubbs EG, Fisher SB, Xu L, Busaidy NL, Cabanillas ME, Castellanos LE, Dadu R, Hamidi S, Hu MI, Waguespack SG, Zafereo ME. Neoadjuvant Targeted Therapy for Locally Advanced Differentiated Thyroid Carcinoma. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
4. Dadu R, Cabanillas, Hamidi, Hu, Waguespack, Busaidy, Vickers, Gupta, Adib, Gule-Manroe. Safety and Efficacy of Second Dose of AIC100 CAR T-cell in Patients with Poorly Differentiated (PDTC) and Aanaplastic Thyroid Carcinoma (ATC). 2025 American Thyroid Association Annual Meeting 2025, 2025. e-Pub 2025.
5. Dadu R, Palacios, Hamidi, Abubaker, Cabanillas ME, Zafereo ME, Iyer, Wang, Banuchi, Maniakas, Mansour, Gunn, Kwon. Clinicopathological Features of Papillary Thyroid Cancer (PTC)-to-Anaplastic Thyroid Carcinoma (ATC) Transformation. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
6. Hamidi S, Busaidy NL, Iyer PC, Dadu R, Gule-Monroe R, Maniakas A, Wang JR, Banuchi V, Zafereo ME, Cabanillas ME. Addition of VEGF or mTOR Inhibition to BRAF-targeted Therapy in BRAFV600E-mutated ATC. 2025 American Thyroid Association Annual Meeting, 2025. e-Pub 2025.
7. Zafereo ME, Cabanillas ME, Maniakas A, Wang JR, Chinn SB, Mady LJ, Fisher SB, Graham PH, Grubbs EG, Seim NB, Banuchi VE, Gule-Monroe MC, Williams MD, Xu L, Busaidy NL, Dadu R, Hamidi S, Iyer PC, Waguespack SG, Sherman SI, Nabhan FS, Ball DW, Worden FP, Hu MI. Neoadjuvant Treatment with Selpercatinib for RET-Altered Thyroid Cancer: A Multicenter Phase 2 Clinical Trial. 2025 American Thyroid Association Annual, 2025. e-Pub 2025.
8. Fournier I, Jorge Eduardo AP, Mahmoud Innab MK, Zafereo ME, Wang JR, Gross ND, Lango MN, Goepfert RP, Sturgis EM, Grubbs EG, Graham PH, Gupta SK, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Hu MI, Iyer P, Waguespack S, Ahmed S, Kwon M, Banuchi VE, Maniakas A, Hosseini SM, Williams MD. Prognostic Significance of BRAFV600E Status In Patients Diagnosed With Papillary Thyroid Cancer (PTC). 17th International Thyroid Congress Scientific Program 2025, 2025. e-Pub 2025.
9. Hamidi S, Vodopivec DM, Busaidy NL, Gule-Monroe MK, Akhave NS, Banuchi VE, Ferraroto R, Gunn G, Iyer PC, Lee A, Maniakas A, Ning MS, Sousa LG, Spiotto MT, Waguespack SG, Wang JR, Zafereo ME, Cabanillas ME, Dadu R. Real-World Experience With Lenatinib Plus Pembrolizumab In Metastatic BRAF Wild -Type Anaplastic Thyroid Carcinoma (BRAFWT-ATC). 17th International Thyroid Congress Scientific Program 2025, 2025. e-Pub 2025.
10. Fournier I, Waguespack SG, Castellanos L, Iyer P, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Williams MD, Palacios JA, Monroe MG, Banuchi VE, Wang JR, Maniakas A, Zafereo ME. Neoadjuvant Larotrectinib Before Surgery For NTRK Fusion-Positive Thyroid Cancer: A Case Series. 17th International Thyroid Congress Scientific Program 2025, 2025. e-Pub 2025.
11. Cubb T, Iyer P, Roecker Z, Sood A, Jazaeri A, Ramalingam P, Hamidi S, Dadu R, Ying A, Busaidy N, Waguespack S, Hu M, Sherman S, Cabanillas M. Malignant Struma Ovarii (MSO) Clinical Characteristics And Outcomes: A Retrospective Tertiary Cancer Center Experience. 17th International Thyroid Congress Scientific Program 2025, 2025. e-Pub 2025.
12. Marczyk VR, Hamidi S, Zafereo M, Waguespack SG, Dadu R, Busaidy NL, Iyer PC, Maniakas A, Banuchi V, Cabanillas ME, Wang JR. Characterization Of The Genomic Landscape Of BRAF-, RAS-, And Fusion-Negative Thyroid Carcinomas Underscores The Role Of Tumor Suppressor Genes Available. 17th International Thyroid Congress Scientific Program 2025, 2025. e-Pub 2025.
13. Ebrahimi S, Hamidi S, Baser HD, Ryoo Ali HJ, Koutroumpakis E, Kumar S, Cabanillas ME, Dadu R, Iyer PC, Hu MI, Busaidy NL, Waguespack SG, Mouhayar EN, Palaskas NL, Deswal A. Emergence of Hypertension in Thyroid Cancer Patients on BRAF ± MEK Inhibitors: A Closer Look at Incidence and Contributing Risk Factors. 2025 American Heart Association Annual Meeting, 2025. e-Pub 2025.
14. Fournier I, Maniakas A, Wang JR, Banuchi V, Lai SY, Gule-Monroe MK, Ning MS, Williams MD, Li X, Dadu R, Busaidy NL, Iyer PC, Hamidi S, Cabanillas ME, Zafereo ME. Neoadjuvant BRAF/MEK inhibitor therapy and immunotherapy for BRAFV600E-mutated anaplastic thyroid cancers. AHNS 2025 Annual Meeting, 2025. e-Pub 2025.
15. Abdallah D, Hamidi S, Dadu R, Busaidy NL, Iyer PC, Waguespack SG, Zafereo ME, Cabanillas ME. Characterization and Clinical Outcomes. 2024 American Thyroid Association Annual Meeting Thyroid, 2024. e-Pub 2024.
16. Ning MS, Dudzinski SO, Busaidy NL, Dadu R, Hamidi S, Welsh J, Gunn B, Waguespack SG, Hu MI, Marczyk VR, Spiotto M, Phan J, Reddy JP, Lee A, Ludmir EB, Maniakas A, Iyer P, Beckham T, Zafereo MA, E Cabanillas AM. Consolidative radiotherapy for oligometastatic and oligoprogressive anaplastic thyroid carcinoma: the potential utility of local therapy for limited distant sites. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
17. Castellanos LE, Hamidi S, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Iyer PC, Roy-Chowdhuri S, Sherman SI, Sura G, Wang JR, Williams MD, Iorgulescu JBL, Waguespack SGL. RAF Family Fusions in Thyroid Carcinomas: Clinicopathological Analysis of 16 Patients. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
18. Hamidi S, Maniakas A, Roy-Chowdhuri S, Hosseini S, Dadu R, Waguespack SG, Hu MI, Sherman SI, Iyer PC, Marczyk VR, Guise TA, Hofmann MC, Busaidy NL, Wang JR, Zafereo ME, Cabanillas ME. Clinicopathological Features of Advanced, RAS-driven Differentiated Thyroid Carcinoma. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
19. Houl JH, Yarmand R, Mendez PM, Henderson Y, Wang JR, Hamidi S, Maniakas A, Iyer PC, Lai SY, Cabanillas M, Busaidy NL, Dadu R, Zafereo M, Hofmann AM. Role of ETV5/p38 signaling Axis in BRAF-Mutated. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
20. Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman BM, Williams MD, Zafereo ME, Wang RJ, Lu C, Ning MS, McKinley B, Woodman SE, Duose DY, Gunn GB, Busaidy NL, Cabanillas ME. Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
21. Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman BM, Williams MD, Zafereo ME, Wang RJ, Lu C, Ning MS, McKinley B, Woodman SE, Duose DY, Gunn GB, Busaidy NL, E Cabanillas AM. Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
22. Hamidi S, Castellanos LE, Thosani S, Best CJ, Sherman SI, Dadu R, Brinkman AK, Khoja M, Hu MI, Waguespack SG, Weitzman SP. Real-Life Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy. 2024 Annual Meeting of the Endocrine Society, 2024. e-Pub 2024.
23. Ramos HE, Hamidi S, Faria SC, Dadu R, Hu MI, Busaidy NL, Waguespack SG, Weitzman S, Sherman SI, Cabanillas ME. Redifferentiation therapy (RDT) in differentiated thyroid carcinomas (DTC): Real-World data of a large cohort of patients. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
24. Abubaker A, Henderson Y, Wang JR, Zafereo M, Banuchi V, Goswami M, Cabanillas ME, Busaidy N, Dadu R, Iyer P, Hamidi S, Williams M, Hosseini S, Lai SY, Maniakas A. Challenges and factors affecting successful patient-derived xenograft model establishment for anaplastic thyroid cancer. 2024 American Thyroid Association Annual Meeting Thyroid, 2024. e-Pub 2024.
25. Cabanillas ME, Busaidy NL, Iyer PC, Gule-Monroe M, Gunn GB, Spiotto MT, Akhave N, Sousa L, Ferrarotto R, Zafereo ME, Wang RJ, Maniakas A, Liu S, Fellman B, Hamidi S, Dadu R. Adjuvant pembrolizumab (pembro) after multimodal therapy for anaplastic thyroid cancer. 2024 American Thyroid Association Annual Meeting, 2024. e-Pub 2024.
26. Hamidi S, Iyer PC, Gule-Monroe MK, Maniakas A, Dadu R, Zafereo ME, Wang J, Busaidy NL, Cabanillas ME. Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC). Society for Immunotherapy of Cancer 38th Annual Meeting 2023, 2023. e-Pub 2023.
27. Ning M, Dudzinski S, Busaidy N, Dadu R, Welsh J, Hu M, Hamidi S, Marczyk VR, Gunn B, Wang C, Waguespack S, Phan J, Beckham T, Chang J, Sherman S, Reddy J, Ying A, O'Reilly M, Chen A, Lee A, Gandhi S, Liao Z, Ludmir E, Nguyen Q, Tang C, Lin S, Zafereo M, Cabanillas M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Differentiated Thyroid Carcinoma: A Potential Strategy to Defer Escalation of Systemic Therapy. 2023 American Thyroid Association Annual Meeting, 2023. e-Pub 2023.
28. Hamidi S, Iyer P, Gule‐Monroe M, Maniakas A, Dadu R, Zafereo M, Wang J, Busaidy N, Cabanillas M. Checkpoint Inhibition in Addition to Dabrafenib + Trametinib for BRAFV600E Mutated Anaplastic Thyroid Carcinoma. 2023 American Thyroid Association Annual Meeting, 2023. e-Pub 2023.
29. Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precision Oncology, 2022. e-Pub 2022. PMID: 35977347.
30. Jeun R, Yedururi S, Lavis V, Best C, Varghese J, Dadu R, Glitza IC, Thosani S. Pancreatic Volumes in Immune Checkpoint Inhibitor-Induced Diabetes. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
31. Gordon M, Roszik J, Cabanillas ME, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Elamin YY, Cascone T, Byers LA, Blumenschein GR, Fossella FV, Naing A, Hong DS, Heymach J, Meric-Bernstam F, Subbiah V. Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
32. Haugen B, French JD, Worden F, Konda B, Sherman EJ, Dadu R, Gianoukakis AG, McCue S, Foster N, Bowles DW, Wirth LJ. Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group ESMO 2020. Annals of Oncology 31(Supplement 4):Pages S1086-S1087, 2020. e-Pub 2020.
33. Haugen BR, French JD, Worden FP, Konda B, Sherman EJ, Dadu R, Gianoukakis AG, McCue SA, Foster N, Bowles DW, Wirth LJ. Lenvatinib plus Pembrolizumab Combination Therapy in Patients with Radioiodine-Refractory (RAIR), Progressive Differentiated Thyroid Cancer (DTC): Results of a Multicenter Phase II International Thyroid Oncology Group Trial. ASCO20 Virtual Scientific Program, 2020. e-Pub 2020.
34. Cabanillas ME, Dadu R, Ferrarotto R, Liu S, Fellman B, Gross N, Gule-Monroe M, Lu C, Grosu H, Williams M, Duose D, Mallampati S, Dervin S, Mckenna Jr EF, Wang JR, Zafereo M, Busaidy NL. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). ASCO20 Virtual Scientific Program, 2020. e-Pub 2020.
35. Brown SJ, Gruschkus SK, Waguespack SG, Dadu R, Zafereo M, Cabanillas ME, Grubbs EG, Sherman SI, Hu MI. RAS-Mutated Sporadic Medullary Thyroid Cancer: A Single-Center Experience. ASCO20 Virtual Scientific Program, 2020. e-Pub 2020.
36. Fazeli S, Dadu R, Waguespack SG, Sherman SI, Busaidy NL, Hu M, Jimenez C, Habra MA, Williams M, Altameemi L, Poropatich K, Routbort MJ, Luthra R, Patel KP, Cabanillas M. TRK-fusion Thyroid Cancer: Clinical Characteristics and Molecular Patterns. Journal of the Endocrine Society Volume 4((Issue Supplement_1, April-May 2020)), 2020. e-Pub 2020.
37. Dadu R, Capdevila J, Elisei R, Hoff A, Tahara M, Sherman E, Leboulleux S, Wirth L, Rothenberg M, Sashegyi A, Soldatenkova V, Lin B, Wright J, Brose M, Robinson B, Hu M. LIBRETTO-531: A phase 3 study of selpercatinib vs investigator choice of cabozantinib or vandetanib in patients with kinase inhibitor-naïve advanced or metastatic RET-mutant medullary thyroid cancer (MTC). AACR Virtual Annual Meeting 2020, 2020. e-Pub 2020.
38. Hu M, Cote G, Hai T, Busaidy N, Cabanillas ME, Dadu R, Gagel R, Grubbs E, Habra M, Jimenez C, Subbiah V, Waguespack S, Williams M, Zafereo M, Sherman S. Emergence of Resistance-Associated Mutations of RET V804M and KRAS in Medullary Thyroid Carcinoma (MTC) Patients Treated with Tyrosine Kinase Inhibitors (TKI) Cabozantinib and Vandetanib. 89th Annual Meeting of the American Thyroid Association, 2019. e-Pub 2019.
39. Chaudhri A, Cabanillas ME, Dadu R, Busaidy N, Cote G, Chowdhuri R, S. Immunohistochemical (IHC) Testing Versus Next Generation Sequencing (NGS) for Identification of BRAF V600E Mutations in Clinical Practice for Anaplastic Thyroid Cancer. 89th Annual Meeting of the American Thyroid Association, 2019. e-Pub 2019.
40. Sperling J, Maniakas A, Cote G, Dadu R, Busaidy N, Lai S, Gross N, Goepfert R, Sturgis E, Zafereo M, Cabanillas ME, Wang RG. Prior cancers among patients newly diagnosed with anaplastic thyroid carcinoma: prevalence and impact on survival. 89th Annual Meeting of the American Thyroid Association, 2019. e-Pub 2019.
41. Falcone R, Waguespack S, Dadu R, Sherman S, Busaidy N, Hu M, Jimenez C, Weitzman S, Cabanillas ME. Redifferentiation radioiodine (RAI)-therapy in patients (pts) with metastatic papillary, follicular and poorly differentiated thyroid cancer (TC). 89th Annual Meeting of the American Thyroid Association, 2019. e-Pub 2019.
42. Maniakas A, Dadu R, Wang GR, Busaidy N, Hofmann MC, Sperling J, Gross N, Sturgis N, Goepfert R, Lai S, Cabanillas ME, Zafereo M. Revolutionizing the therapeutic landscape of a deadly disease. 89th Annual Meeting of the American Thyroid Association, 2019. e-Pub 2019.
43. Fazeli S, Guille-Monroe M, Cabanillas ME, Busaidy NL, Hu MI, Sherman SI, Waguespack SG, Jimenez C, Habra M, Cote G, Hofmann MC, Bassett R, Dadu R. Response to BRAF with/without MEK inhibitors in BRAFV600E plus TERT promoter mutated differentiated thyroid cancers. 89th Annual Meeting of the American Thyroid Association, 2019. e-Pub 2019.
44. Leboulleux, S, Colevas D, Liu Y, Ramsingh G, Pal S, Dadu R. Phase 1b (COSMIC-021) Trial of Cabozantinib Alone or in Combination With Atezolizumab in Patients With Solid Tumors including Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer (DTC). 2019 World Congress on Thyroid Cancer (WCTC), 2019. e-Pub 2019.
45. Wang Y, Abu-Sbeih H, Ali F, Altan M, Dadu R, Jazaeri A. Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor-induced colitis. J Clin Oncol Volume 37, 2019 (suppl; abstr 2571), 2019. e-Pub 2019.
46. Abdel-Wahab N, Yu RK, Diab A, Dadu R, Shannon V, Futreal A, Criswell LA, Shete S, Suarez-Almazor ME. Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibitors. J Clin Oncol 15_suppl.2586, 2019. e-Pub 2019.
47. Cabanillas ME, Busaidy N, Dadu R, Ferrarotto R, Gross N, Gule-Monroe M, Lu C, Grosu H, Williams M, Zafereo M. Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility. Journal of the Endocrine Society Volume 3(Issue Supplement_1, April-May 2019 OR27-6), 2019. e-Pub 2019.
48. Agosto S, Waguespack S, Gilbert C, Hess K, Habra M, Jimenez C, Hu M, Sherman S, Busaidy N, Dadu R, Tatsui C, McCutcheon I, Grubbs E, Williams, M, Shah K, Cabanillas. Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy. J Endocr Soc. 2019(3(Suppl 1)), 2019. e-Pub 2019.
49. Dadu R, Cabanillas ME, de Groot P, Chang JY, Tang C, Sherman SI, Busaidy NL, Waguespack SG, Hu MI, Ying A, Habra M, Menon H, Welsh J. Ipilimumab with stereotactic ablative radiation therapy (SABR): Results of a thyroid cancer expansion cohort. The 88th Annual Meeting of the American Thyroid Association, 2018. e-Pub 2018.
50. Wang JR, Zafereo M, Dadu R, Ferrarotto R, Busaidy N, Lu C, Ahmed S, Williams M, Sturgis E, Goepfert R, Gross N, Lai S, Gunn B, Rosenthal D, Phan J, Fuller D, Morrison W, Iyer P, Cabanillas ME. Neoadjuvant targeted therapy followed by surgical resection in BRAF mutated anaplastic thyroid carcinoma. The 88th Annual Meeting of the American Thyroid Association, 2018. e-Pub 2018.
51. Qin Y, Wang JR, Iyer P, Cote G, Busaidy N, Dadu R, Zafereo M, Williams M, Ferrarotto R, Gunn B, Cabanillas ME. Clinical utility of plasma cell-free DNA in anaplastic thyroid cancer. The 88th Annual Meeting of the American Thyroid Association, 2018. e-Pub 2018.
52. Simmons G, Hguyen H, Kaya D, Ahmed S, Dadu R, Cabanillas ME, Waguespack S, Shah K. Imaging Findings of Cancer Immunotherapy Induced Hypophysitis, an Update. American Society of Neuroradiology 56th Annual Meeting, 2018. e-Pub 2018.
53. Wang G, Cote G, Zafereo M, Iyer P, Dadu R, Busaidy NL, Gross NL, Sturgis E, Ferrarotto R, Charles L, Gunn GB, Myers JN, Lai SY, Williams MD, Cabanillas ME. Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival. J Clin Oncol 2018 (suppl; abstr 6023), 2018. e-Pub 2018.
54. Zagzag J, Tzeng CWD, Dadu R, Scally CP, Perrier ND. A 3-decade surprise. American Association of Endocrine Surgery, 2018. e-Pub 2018.
55. Nguyen H, Shah K, Waguespack S, Habra M, Hu MI, Iyer P, Kaya D, Pitteloud M, Diab A, Subudhi S, Dadu R. Immune-related hypophysitis (irH) is a known side effect of immune checkpoint inhibitors (ICI). The Endocrine Society's 100th Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
56. Iyer P, Best C, Lavis V, Varghese JM, Dadu R, Thosani SN. Checkpoint inhibitor mediated insulin dependent diabetes: A Cancer Center Experience. The Endocrine Society's 100th Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
57. Iyer P, Ferrarotto R, Gule-Monroe M, Busaidy N, Dadu R, Habra M, Williams MD, Hofmann M, Zafereo M, Skinner H, Cabanillas ME. Pembrolizumab added to Kinase Inhibitor (KI) therapy in Anaplastic Thyroid Carcinoma (ATC): A Single Cancer Center's Experience. 87th Annual Meeting of the American Thyroid Association, Victoria, BC, Canada, 2017. e-Pub 2017.
58. Iyer P, Cote GJ, Dadu R, Ferrarotto R, Busaidy NL, Hofmann M, Zafereo M, Williams MD, Subbiah V, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA Detected by Droplet Digital PCR (DDPCR) as a Biomarker in the Management of Anaplastic Thyroid Carcinoma (ATC) Patients. 87th Annual Meeting of the American Thyroid Association, Victoria, BC, Canada, 2017. e-Pub 2017.
59. Busaidy N, Cabanillas ME, Sherman S, Habra MA, Dadu R, Hu MI, Jimenez C, Waguespack SG, Subbiah V, Ying AK, Gagel RF, Cote G. Emergence of V804M resistance gatekeeper mutation in sporadic medullary thyroid carcinoma patients treated with TKI tyrosine kinase inhibitors. 87th Annual Meeting of the American Thyroid Association, Victoria, BC, Canada, 2017. e-Pub 2017.
60. Iyer P, Cote GJ, Dadu R, Busaidy N, Ferrarotto R, Hess KR, Gule-Monroe M, Subbiah V, Hofmann M, Gross ND, Zafereo M, Cabanillas ME. Circulating BRAFV600E cell-free DNA (cfDNA) detected by droplet digital PCR (ddPCR) as a biomarker for monitoring response to therapy in the management of BRAF mutated (BRAFm) anaplastic thyroid carcinoma (ATC) patients. 87th Annual Meeting of the American Thyroid Association, Victoria, BC, Canada, 2017. e-Pub 2017.
61. Welsh JW, Tang C, de Groot P, Naing A, Raju U, Shaaban S, Chang SY, Cushman T, Heymach J, Dadu R, Cabanillas ME, Hess K, Massarelli E, Subbiah V, Fu S, Papadimitrakopoulou V, Gomez DR, Hahn SM, Komaki RU, Hong D. Phase II 5-arm trial of ipilimumab plus lung or liver stereotactic radiation for patients with advanced malignancies. ASTRO's 59th Annual Meeting, San Diego, CA, 2017. e-Pub 2017.
62. Jaber T, Milton D, Grubbs E, Trotter CS, Zafereo M, Cabanillas ME, Dadu R, Cote G, Hu MI. The Utility of the Calcitonin (Ctn) to Carcinoembryogenic Antigen (CEA) Ratio (CCR) in Prognostication of Medullary Thyroid Carcinoma (MTC). 3rd World Congress on Thyroid Cancer, Boston, MA, 2017. e-Pub 2017.
63. Cubb T, Patel S, Tajuddin N, Goodale T, Rodgers T, Trinh VA, Tawbi H, Dadu R. Primary Hypoparathyroidism: A New Endocrine Immune Related Adverse Event (irAEs) Secondary to Combination Treatment with PD-1 and CTLA-4 Checkpoint Inhibitors. The Endocrine Society's 99th Annual Meeting, Orlando, FL, 2017. e-Pub 2017.
64. Jaber T, Waguespack SG, Cabanillas ME, Vu T, Santos EB, Dadu R, Busaidy NL. Efficacy of Targeted Therapy in Resensitization to Radioactive Iodine (RAI) in Advanced Thyroid Cancer: The MD Anderson Experience. The Endocrine Society's 99th Annual Meeting, Orlando, FL, 2017. e-Pub 2017.
65. Kutahyalioglu M, Kwatampora LJ, Korivi BR, Ibrahim EY, Zhou S, Cabanillas ME, Jimenez C, Dadu R, Habra MA, Fogelman D, Busaidy NL. The Effects of Kinase Inhibitors on Body Composition in Endocrine Tumor Patients- Pilot Study. The Endocrine Society's Annual Meeting, Orlando, FL, 2017. e-Pub 2017.
66. Jaber T, Hyde SM, Cote G, Grubbs EG, Dadu R. A Homozygous RET K666N Genotype with an MEN2A Phenotype. The Endocrine Society's 99th Annual Meeting, Orlando, FL, 2017. e-Pub 2017.
67. Iyer P, Dadu R, Busaidy NL, Ferrarotto R, Gule-Monroe MK, Lu C, Williams MD, Cabanillas ME. Harvesting high-hanging fruit: Targeted Therapy for BRAF mutant (BRAFm) and BRAF wild-type (BRAFwt) Anaplastic Thyroid Cancer (ATC) patients (pts). 86th Annual Meeting of The American Thyroid Association, Denver, CO, 2016. e-Pub 2016.
68. Dadu R, Vilalabos, PA, Cuentas P, ER, Canales R, J, Wistuba, II, Zhou, S, Williams, M, Cabanillas, ME. Anaplastic thyroid cancer (ATC) is a hot immunogenic environment: Immunoprofiling of a large cohort of ATC tumors. 86th Annual Meeting of the American Thyroid Association, Denver, CO, 2016. e-Pub 2016.
69. Iyer P, Cabanillas ME, Waguespack SG, Busaidy NL, Hu MI, Dadu R. Immunotherapy-related destructive thyroiditis: A Cancer Center Experience. 86th Annual Meeting of the American Thyroid Association, Denver, CO, 2016. e-Pub 2016.
70. Arango M, Dadu R, Ying AK, Sellin RV, Waguespack SG. The Prevalence and Implications of Positive Thyroglobulin Autoantibodies in Children at Diagnosis of Differentiated Thyroid Cancer. The Endocrine Society's 98th Annual Meeting, Boston, MA, 2016. e-Pub 2016.
71. Rao S, Dadu R, Busaidy N, Lai S, Gunn B, Lu C, William W, Cabanillas ME. Patterns of failure in anaplastic thyroid cancer (ATC) patients (pts). The Endocrine Society's 98th Annual Meeting, Boston, MA, 2016. e-Pub 2016.
72. Shah K, Ahmed S, Cabanillas ME, Pitteloud M, Waguespack S, Dadu R. Imaging Findings of Cancer Immunotherapy Induced Hypophysitis. The American Society of Neuroradiology 53rd Annual Meeting, 2015. e-Pub 2015.
73. Kwatampora L, Cabanillas ME, Korivi BR, Fogleman D, Dadu R, Dalal S, Busaidy NL. Effect of Cabozantinib on Body Composition in Advanced Thyroid Cancer. The Endocrine Society's 97th Annual Meeting, San Diego, CA, 2015. e-Pub 2015.
74. Pitteloud MJ, Dadu R, Cabanillas ME, Shah K, Hu MI, Habra MA, Waguespack SG. Hypophysitis in the Age of Cancer Immunotherapy: Experience in a Large Cancer Center. The Endocrine Society’s 97th Annual Meeting, San Diego, CA, 2015. e-Pub 2015.
75. Weitzman SP, Peicher KT, Dadu R, Hu MI, Jimenez C, Gardner C, Qayyum A, Hernandez M, Cabanillas, ME. Salvage therapy: When a tyrosine kinase inhibitor (TKI) fails in advanced medullary thyroid cancer (MTC). The Endocrine Society’s 97th Annual Meeting, San Diego, CA, 2015. e-Pub 2015.
76. Dadu R, Rodriguez Canales J, Wistuba II, Tian W, Lui H, Williams MD, Cabanillas ME. Targeting immune system in anaplastic thyroid cancer (ATC): a potential treatment approach. 15th International Thyroid Congress, Orlando, FL, 2015. e-Pub 2015.
77. Cabanillas ME, Dadu R, Waguespack SG. Response to dabrafenib and trametinib in a patient BRAF V600E-mutated (BRAFm) Anaplastic Thyroid Cancer (ATC). 15th International Thyroid Congress, Orlando, FL, 2015. e-Pub 2015.
78. Pena Jr I, Clayman GL, Sturgis E, Lee J, Grubbs EG, Dadu R, Waguespack SG, Sherman SI, Zafereo M. Lateral neck disease in patients with sporadic medullary thyroid cancer. 15th International Thyroid Congress, Orlando, FL, 2015. e-Pub 2015.
79. Dadu R, Rodriguez Canales J, Wistuba II, Tian W, Lui H, Grubbs EG, Cote G, Ray G, Williams M, Cabanillas ME. Immune markers in medullary thyroid cancer (MTC) and their clinical significance. 15th International Thyroid Congress, Orlando, FL, 2015. e-Pub 2015.
80. Cabanillas ME, Waguespack S, Pitteloud M, Roman-Gonzalez A, Jessop A, Santos E, Davies M, Dadu R. Anti-CTLA4-induced Graves Disease (GD): A rare cause of hyperthyroidism in 3 patients with metastatic melanoma. 15th International Thyroid Congress, Orlando, FL(2015), 2015. e-Pub 2015.
81. Dadu R, Hu, MI, Cleeland CS, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying AK, Fox P, Cabanillas ME. The efficacy of the natural clay, CASAD, in reducing medullary thyroid cancer -related diarrhea and its effects on quality of life: a pilot study. 84th Annual Meeting of the American Thyroid Association, Coronado, CA, 2014. e-Pub 2014.
82. Dadu R, Shah K, Bassett R, Busaidy N, Waguespack S, Sherman SI, Habra M, Jimenez C, Hu M, Ying A, Cabanillas ME. Is there an alternative treatment option for patients with advanced papillary thyroid cancer (PTC) harboring the BRAFV600E mutation?. The 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting, Chicago, IL, 2014. e-Pub 2014.
83. Busaidy NL, Cabanillas ME, Dadu R, Jimenez C, Habra, Vaporciyan A, Morris L, Perrier ND, Hoff, AO. Metastatic parathyroid carcinoma and hypercalcemia responds to treatment with sorafenib. The 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting, Chicago, IL, 2014. e-Pub 2014.
84. Cabanillas ME, Dadu R, Sturgis EM. Neoadjuvant Vemurafenib for locally advanced papillary thyroid cancer harboring BRAF V600E mutation: case report. American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress, Las Vegas, NV, 2014. e-Pub 2014.
85. Valdes C, Nagy C, Dadu R. Testosterone secreting tumor or insulin resistance? Metformin as a diagnostic and therapeutic trial. American Society for Reproductive Medicine Meeting and the International Federation of Fertility Societies' World Congress, Boston, MA, 2013. e-Pub 2013.
86. Dadu R, Devine C, Hernandez M, Busaidy NL, Waguespack SG, Hu MI, Ying AK, Habra MA, Jimenez C, Sellin R, Cote G, Sherman SI, Cabanillas ME. Survival and Efficacy of Tyrosine Kinase Inhibitors after First Line Sorafenib Failure in Patients with Advanced Differentiated Thyroid Cancer. 83rd Annual Meeting of the American Thyroid Association, San Juan, PR, 2013. e-Pub 2013.
87. Adili A, Chasen B, Dadu R, Williams M, Ali S, Sellin R, Habra MA, Cote G, Busaidy NL, Jimenez C, Hu MI, Waguespack SG, Sherman SI, Cabanillas ME. Outcomes of Patients with Poorly Differentiated Thyroid Cancer of Follicular Origin Treated with First Line Sorafenib. 83rd Annual Meeting of the American Thyroid Association, San Juan, PR, 2013. e-Pub 2013.
88. Dadu R, Shah C, Waguespack S, Sherman SI, Habra M, Busaidy N, Jimenez C, Ying A, Hu M, Cabanillas ME. Efficacy and tolerability of vemurafenib in BRAFV600E positive papillary thyroid cancer. 83rd Annual Meeting of the American Thyroid Association, San Juan, PR, 2013. e-Pub 2013.
89. Dadu R, Busaidy N, Habra M, Hu M, Jimenez C, Ying A, Waguespack S, Cabanillas ME. Off Label Use of Sorafenib in Patients with Differentiated Thyroid Cancer: Focus on Tolerability Profile. American Association of Clinical Endocrinologists Annual Meeting and TESS Surgical Symposium, 2013. e-Pub 2013.
90. Dadu R, Busaidy N, Habra M, Hu M, Jimenez C, Ying A, Waguespack S, Cabanillas ME. Off label use of sorafenib in patients with differentiated thyroid cancer: Focus on tolerability profile. Texas Chapter of American Association of Clinical Endocrinologists Annual Meeting and The Texas Endocrine Surgical Symposium, Austin, TX, 2013. e-Pub 2013.
91. Dadu R, Waguespack S, Cabanillas M. Indeterminate thyroid nodules on cytology: Should presence of RAS mutation change management?. The Endocrine Society 95th Annual Meeting, San Francisco, CA, 2013. e-Pub 2013.
92. Ali SK, Dadu R, Lu C, Grubbs E, Blevins D, Cabanillas ME. Peculiar presentation of papillary thyroid cancer. The Endocrine Society 95th Annual Meeting, San Francisco, CA, 2013. e-Pub 2013.
93. Dadu R, Hu M, Habra M, Waguespack S, Ying A, Busaidy N, Cabanillas M. Salvage therapy with tyrosine kinase inhibitors for differentiated thyroid carcinoma after first line sorafenib failure. The Endocrine Society 95th Annual Meeting, San Francisco, CA, 2013. e-Pub 2013.
94. Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack S, Ying A, Habra M, Thosani S, Hu M, Cabanillas M. Is 2nd line targeted therapy beneficial in patients with differentiated thyroid cancer after 1st line sorafenib failure?. J Clin Oncol Volume 31, 2013. e-Pub 2013.
95. Dadu R, Lu C, Piha-Paul S, Cote G, Cabanillas M. Dual somatic mutations in BRAF V600E and PIK3CA in patients with aggressive papillary thyroid cancer: Report of 3 cases. 82nd Annual Meeting of the American Thyroid Association, Quebec City, Canada, 2012. e-Pub 2012.
96. Dadu R, Thosani S, Nalini R. Hyperammonemia hyperinsulinemia syndrome complicated by gestational diabetes: Treatment challenges. The Endocrine Society 94th Annual Meeting, Houston, TX, 2012. e-Pub 2012.
97. Dadu R, Habra M, Williams M, Hu M. Metastatic papillary thyroid carcinoma to the kidney – 30 years after initial diagnosis. The Endocrine Society 94th Annual Meeting, Houston, TX, 2012. e-Pub 2012.
98. Kim J, Dadu R, Nalini R. Recurrent pericardial effusion and shock due to hypothyroidism and adrenal crisis: A case of unrecognized sheehan's syndrome. The Endocrine Society 94th Annual Meeting, Houston, TX, 2012. e-Pub 2012.
99. Horowitz D, Dadu R, Parperis K, Giannelou A, Bansal A, Logue M, Kaufman D. Platypnea-orthodeoxia syndrome after right pneumonectomy: Does a PFO explain the degree of refractory hypoxemia?. American College of Physicians, Connecticut Chapter Meeting, Connecticut, 2010. e-Pub 2010.
100. Dadu R, Dadu RT, Lall P, Zarich S. Thyrotoxic periodic paralysis. American College of Physicians, Connecticut Chapter Meeting, Connecticut, 2010. e-Pub 2010.
101. Dadu R, Shimshi M. Milk-alkali syndrome is a major cause of severe hypercalcemia. American Association of Clinical Endocrinologists 19th Annual Meeting, Boston, MA, 2010. e-Pub 2010.
102. Dadu RT, Dadu R, Dhawan P, Saul Z. Unusual presentation of endocarditis with Nutritional Variant Streptococci. American College of Physicians, Connecticut Chapter Meeting, Connecticut, 2009. e-Pub 2009.
103. Ong P, Casanegra AI, Brannan S, Dadu R, Berner M, Spinning K, Hughes T, Marrinan G, Zinn K, Manthous C. Brief femoral catheterization rarely causes thrombosis or bacteremia. American College of Physicians, Connecticut Chapter Meeting, Connecticut, 2009. e-Pub 2009.
104. Dadu R, Shimshi M. The cost-effectiveness of routine white blood cell count monitoring in antithyroid drug-induced agranulocytosis. 79th Annual Meeting of the American Thyroid Association, Palm Beach, FL, 2009. e-Pub 2009.
105. Dadu R, Dadu RT, Shimshi M. Milk-alkali syndrome is a major cause of severe hypercalcemia. American College of Physicians, Connecticut Chapter Meeting, Connecticut, 2009. e-Pub 2009.
106. Parperis K, Dadu R, Nair S, Hoq S, Argento V. Thyrotoxic dysphagia in an 82 year old male. American College of Physicians, Connecticut Chapter Meeting, Connecticut, 2009. e-Pub 2009.
107. Gheorghe C, Vazquez R, Ramos F, Dadu R, Amoateng-Adjepong Y, Manthous C. Gurgling predicts hospital-acquired pneumonia. American College of Physicians, Connecticut Chapter Meeting, Connecticut, 2009. e-Pub 2009.
108. Gheorghe C, Vazquez R, Casanegra A, Dadu R, Feng Y, Argento V, Manthous C. Elders’ predilections regarding acute on chronic (incapacitating) illness. American Thoracic Society International Conference, San Diego, CA, 2009. e-Pub 2009.
109. Dadu R, Grigaryan A, Lall P, Argento V. Thyrotoxic dysphagia in an 82 year old male. American Geriatric Society Annual Meeting, Chicago, IL, 2009. e-Pub 2009.
110. Casanegra AI, Brannan S, Dadu R, Ong P, Berner M, Spinning K, Hughes T, Marrinan G, Manthous C. Is short-term femoral vein catheterization unsafe?. American Thoracic Society International Conference, San Diego, CA, 2009. e-Pub 2009.
111. Gheorghe C, Vazquez R, Dadu R, Berianu F, Feng Y, Blot C, Balasingham A, Kaufman D, Manthous C. Hyperchloremic metabolic acidosis following resuscitation of shock. American Thoracic Society International Conference, 2007. e-Pub 2007.
112. Vodopivec DM, Cabanillas ME, Busaidy NL, Gule-Monroe MK, Zafereo ME, Wang JR, Williams MD, Waguespack SG, Bassett R, Maniakas A, Lai SY, Dadu R. Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer. Poster Plus Presentation at ENDO 2022, Atlanta, GA.
113. Dadu R. BRAF AND MEK INHIBITORS IN THYROID CANCER AND THE HEART: TRACKING THE INCIDENCE OF CARDIAC DYSFUNCTION AND HEART FAILURE,". ACC 75th Annual Scientific Session.

Book Chapters

1. Santillan, MR, Dadu, R, Gagel, RF, Grubbs, EG, Hu, MI. Systemic Therapies for Advanced Medullary Thyroid Carcinoma, 293-307, 2025.
2. Cabanillas ME, Weitzman SP, Dadu R, Gansler T, Zafereo M. Thyroid Cancer. In: The American Cancer Society's Oncology in Practice: Clinical Management. Wiley Blackwell, 2018.
3. Cabanillas ME, Schweppe RE, Dadu R, Cote G, Beadnell TC, Hofmann MC. Translational research and genomics driven trials in thyroid cancer. In: Practical Management of Thyroid Cancer - A Multidisciplinary Approach. 2nd Springer, 2017.
4. Dadu R, Gagel RF, Hu MI. Medical Treatment Decision-Making for Advanced, Progressive Medullary Thyroid Cancer. In: Thyroid Cancer: A Clinical Casebook, 2015.
5. Dadu R, Ahn P, Holsinger C, Hu M. Thyroid and parathyroid cancer. In: Cancer Management 16th Edition, 2014.
6. Dadu R, Ahn P, Holsinger C, Hu M. Thyroid and parathyroid cancer. In: Cancer Management 15th Edition, 2013.

Letters to the Editor

1. Cabanillas ME, Dadu R, Lai SY. In reply. Oncologist 19: e4, 2014.